Pharmaceutical liquid composition, and preparation method therefor and use thereof

By using a combination of glycine or alanine with sodium picosulfate, magnesium oxide, and citric acid in the pharmaceutical liquid composition, the unstable and high and low temperatures of the pharmaceutical liquid composition at lower pH values ​​is solved. Storage problems in the environment achieve stability in a wide pH range and stability improvements in high and low temperatures.

WO2024234674A1PCT designated stage expired Publication Date: 2024-11-21SHENZHEN BEIMEI PHARM CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/070114
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2024-01-02
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

The existing pharmaceutical liquid compositions are unstable within a lower pH range, and are prone to precipitation of magnesium citrate and the generation of impurities degraded by sodium picosulfate, and have high requirements for high and low temperature environments.

Method used

The precipitation of magnesium citrate and magnesium hydroxide is inhibited by forming metal organic complexes, and the pH range is expanded to 3.0-8.0. Improve the stability of the composition.

Benefits of technology

Effectively inhibit the precipitation of magnesium citrate within a wide pH range, reduce the generation of impurities degraded by sodium picosulfate, and significantly improve the stability of the composition at high and low temperatures.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024070114-FTAPPB-I100001
    Figure PCTCN2024070114-FTAPPB-I100001
  • Figure PCTCN2024070114-FTAPPB-I100002
    Figure PCTCN2024070114-FTAPPB-I100002
  • Figure PCTCN2024070114-FTAPPB-I100003
    Figure PCTCN2024070114-FTAPPB-I100003
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical liquid composition, and a preparation method therefor and the use thereof. The pharmaceutical liquid composition comprises water, sodium picosulfate, magnesium oxide, citric acid and an amino acid compound, wherein the amino acid compound is selected from one or a mixture of two of glycine and alanine. The pharmaceutical liquid composition can effectively inhibit the precipitation of magnesium citrate in a wide range of pH value, reduces the generation of sodium picosulfate degradation impurities, and is very stable in both high and low temperature environments.
Need to check novelty before this filing date? Find Prior Art

Description

Liquid pharmaceutical composition, preparation method and application thereof

[0001] This application claims priority to the Chinese invention patent application entitled “Pharmaceutical liquid composition, preparation method and application thereof” and application number 202310558081.6 filed on May 17, 2023. Technical Field

[0002] The present invention relates to the technical field of pharmaceutical preparations, and in particular to a pharmaceutical liquid composition, a preparation method and an application thereof. Background Art

[0003] Sodium picosulfate, whose structure is shown in formula (1), is a laxative synthesized by the Italian company De Angeli in the 1960s. It acts directly on the large intestinal mucosa, producing a mild laxative effect. It is not only used to treat various forms of constipation, but also relieves defecation pain caused by hemorrhoids and anal fissures.

[0004] Compound sodium picosulfate, containing sodium picosulfate, magnesium oxide, and citric acid, is a dual-action laxative. Sodium picosulfate acts directly on the colonic mucosa to stimulate peristalsis, while magnesium oxide reacts with citric acid to form magnesium citrate solution, an osmotic laxative that increases intestinal moisture. This drug is used for bowel cleansing preparation prior to colonoscopy and X-ray examinations.

[0005] Huiling's Compound Sodium Picosulfate Oral Granules Approved by the FDA on July 16, 2012, this drug requires mixing the powder with cold water before taking it orally. However, some patients find it inconvenient to dissolve the drug in water. Furthermore, some patients who lack proper guidance for proper use may place the powder in their mouth before drinking the water. In this case, the exothermic reaction that occurs when the powder dissolves in water can cause burns to the patient's mouth.

[0006] Compound sodium picosulfate oral solution solves this problem. However, in liquid preparations, magnesium oxide and citric acid easily react to form magnesium citrate, which easily precipitates and causes instability in the liquid preparation.

[0007] A liquid pharmaceutical composition containing sodium picosulfate, magnesium oxide and citric acid has been reported. The pH value of the drug is kept low, so that the amount of precipitation in the liquid preparation tends to be reduced. However, the low pH value makes sodium picosulfate unstable and produces impurity A (sodium 4-[(pyridin-2-yl)(4-hydroxyphenyl)methyl]phenyl sulfate). When malic acid is used as a precipitation inhibitor and the pH value is controlled between 4.1 and 5.4, a more stable compound sodium picosulfate oral solution can be obtained. Its product (CLENPIQ TM ) has been marketed as a colon cleanser. The report also showed that malic acid can form a stable cyclic complex with magnesium ions, thus inhibiting the precipitation of magnesium hydroxide, and its effectiveness is greater than that of other carboxylic acids. However, this liquid pharmaceutical composition requires a pH range of 4.1 to 5.4, which is very narrow. Furthermore, this liquid pharmaceutical composition is unstable at low temperatures and requires strict storage conditions.

[0008] Summary of the Invention

[0009] The object of the present invention is to provide a pharmaceutical liquid composition that can effectively inhibit the precipitation of magnesium citrate and reduce the generation of sodium picosulfate degradation impurities within a wide pH range and is very stable under high and low temperature environments.

[0010] The purpose of the present invention is achieved through the following technical solutions:

[0011] In one aspect, the present invention provides a pharmaceutical liquid composition comprising water, sodium picosulfate, magnesium oxide, citric acid, and an amino acid compound;

[0012] The amino acid compound is selected from glycine and alanine One or a mixture of two.

[0013] In one embodiment, the molar ratio of sodium picosulfate, magnesium oxide, citric acid and amino acid compound is (0.001-0.1):(10-200):(10-150):(10-200).

[0014] In one embodiment, the concentration of sodium picosulfate in the pharmaceutical liquid composition is 0.01 mg / ml to 0.2 mg / ml.

[0015] In one embodiment, the pH value of the pharmaceutical liquid composition is 3.0-8.0.

[0016] In one embodiment, the pharmaceutical liquid composition further comprises a pharmaceutically acceptable excipient.

[0017] In one embodiment, the auxiliary material is selected from one or more of a stabilizer, a preservative, a sweetener, a pH adjuster, a flavoring agent and an antioxidant.

[0018] In one embodiment, the stabilizer is selected from one or both of edetate disodium and edetate calcium sodium.

[0019] In one embodiment, the preservative is selected from one or more of sodium benzoate, methylparaben, ethylparaben, propylparaben and butylparaben.

[0020] In one embodiment, the sweetener is selected from one or more of sucralose, sucrose, acesulfame potassium, mannitol and aspartame.

[0021] In one embodiment, the pH regulator is selected from one or more of sodium hydroxide, potassium hydroxide, ammonia solution, triethanolamine, potassium citrate, sodium bicarbonate, potassium bicarbonate and sodium citrate.

[0022] In one embodiment, the fragrance is selected from one or more of sweet orange flavor, strawberry flavor, orange flavor, vanilla flavor and mixed fruit flavor.

[0023] In one embodiment, the antioxidant is selected from one or both of sodium metabisulfite and vitamin C.

[0024] In another aspect, the present invention provides a method for preparing the pharmaceutical liquid composition according to the present invention, comprising the steps of:

[0025] Combine water, sodium picosulfate, magnesium oxide, citric acid, and amino acid compound.

[0026] In one embodiment, the mixing comprises:

[0027] Mixing magnesium oxide and citric acid in water to prepare mixture S1;

[0028] Mixing the mixture S1 with an amino acid compound to prepare a mixture S2;

[0029] The mixture S2 was mixed with sodium picosulfate.

[0030] In another aspect, the present invention provides use of the pharmaceutical liquid composition according to the present invention in the preparation of a laxative.

[0031] In another aspect, the present invention provides use of the pharmaceutical liquid composition according to the present invention in preparing a colon cleansing agent.

[0032] The present invention has the following beneficial effects:

[0033] After extensive creative work, the inventors discovered that glycine and / or alanine can also serve as precipitation inhibitors for compound sodium picosulfate oral solution, and their precipitation inhibition effect is superior to malic acid. It is speculated that the possible reason is that glycine and / or alanine contain carboxyl and amine groups (which are short-chain small molecule amino acids). The oxygen atom of the carboxyl group has a lone pair of electrons, and the nitrogen atom of the amine group has a lone pair of electrons. Both can form metal-organic complexes with free magnesium ions. Short-chain small molecule amino acids can form cyclic complexes with magnesium ions, which effectively inhibit the precipitation of magnesium hydroxide. Moreover, the conditions for forming this metal-organic complex are relatively tolerant. In a wide pH range (3.0-8.0), especially at higher pH values, glycine and / or alanine can inhibit the precipitation of magnesium citrate and reduce the production of sodium picosulfate degradation impurity A (4-[(pyridin-2-yl)(4-hydroxyphenyl)methyl]phenyl sulfate sodium), while significantly improving the stability of the composition under high and low temperature conditions.

[0034] Tests have shown that the liquid pharmaceutical composition comprising water, sodium picosulfate, magnesium oxide, citric acid and the amino acid compound of the present invention is very stable within the temperature range of -20°C to 60°C, has the same effect as the colon cleanser on the market, and has broad application prospects. DETAILED DESCRIPTION

[0035] The present invention will be further described in detail below with reference to specific embodiments. The present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to provide a more thorough and comprehensive understanding of the present disclosure.

[0036] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention pertains. The terms used herein in the specification of the present invention are for the purpose of describing specific embodiments only and are not intended to limit the present invention. The term "and / or" as used herein includes any and all combinations of one or more of the associated listed items.

[0037] Where “including,” “having,” and “comprising” are used herein, it is intended to cover a non-exclusive inclusion, and another component may also be added unless a clear limiting term is used, such as “only,” “consisting of,” etc.

[0038] The words "preferably", "more preferably", "preferably", "better", etc. in the present invention refer to embodiments of the present invention that can provide certain beneficial effects in certain circumstances. However, other embodiments may also be preferred under the same circumstances or other circumstances. In addition, the statement of one or more preferred embodiments does not imply that other embodiments are not applicable, nor is it intended to exclude other embodiments from the scope of the present invention. That is, in the present invention, "preferably", "more preferably", "preferably", "better", etc. are merely descriptions of implementation methods or examples with better effects, but do not constitute a limitation on the scope of protection of the present invention.

[0039] In the present invention, “further”, “further”, “particularly”, etc. are used for descriptive purposes to indicate differences in content, but should not be understood as limiting the scope of protection of the present invention.

[0040] In the present invention, "at least one" means more than one, such as one, two, or more than two. "Multiple" or "several" means at least two, such as two, three, etc. In the description of the present invention, "several" means at least one, such as one, two, etc., unless otherwise specifically defined.

[0041] When a numerical range is disclosed herein, the range is considered continuous and includes the minimum and maximum values ​​of the range, as well as every value between such minimum and maximum values. Further, when a range refers to an integer, every integer between the minimum and maximum values ​​of the range is included. In addition, when multiple ranges are provided to describe a feature or characteristic, the ranges can be combined. In other words, unless otherwise indicated, all ranges disclosed herein are understood to include any and all subranges subsumed therein.

[0042] Unless otherwise specified, all steps of the present invention may be performed sequentially or randomly. For example, the method may include steps (a) and (b), which means that the method may include steps (a) and (b) performed sequentially, or may include steps (b) and (a) performed sequentially. For example, the method may further include step (c), which means that step (c) may be added to the method in any order, for example, the method may include steps (a), (b), and (c), or may include steps (a), (c), and (b), or may include steps (c), (a), and (b), etc.

[0043] Unless mentioned otherwise, terms in the singular may include plural forms and should not be construed as having one number.

[0044] The present invention provides a liquid pharmaceutical composition that can effectively inhibit magnesium citrate precipitation within a wide pH range, reduce the generation of sodium picosulfate degradation impurities, and is very stable under high and low temperature environments.

[0045] The pharmaceutical liquid composition of the present invention comprises water, sodium picosulfate, magnesium oxide, citric acid and an amino acid compound;

[0046] The amino acid compound is selected from glycine and alanine One or a mixture of two.

[0047] Research has found that, in addition to malic acid, glycine and / or alanine can also serve as precipitation inhibitors for compound sodium picosulfate oral solution, and their precipitation inhibition effect is better than malic acid. It is speculated that the possible reason is that glycine and alanine contain carboxyl and amine groups (which are short-chain small molecule amino acids). The oxygen atom of the carboxyl group has a lone pair of electrons, and the nitrogen atom of the amine group has a lone pair of electrons. Both can form metal organic complexes with free magnesium ions. Short-chain small molecule amino acids can form cyclic complexes with magnesium ions, which effectively inhibit the precipitation of magnesium hydroxide. Moreover, the conditions for forming this metal organic complex are relatively tolerant. In a wide pH range (3.0-8.0), especially at higher pH values, glycine and / or alanine can inhibit the precipitation of magnesium citrate and reduce the production of sodium picosulfate degradation impurity A (4-[(pyridin-2-yl)(4-hydroxyphenyl)methyl]phenyl sulfate sodium), while significantly improving the stability of the composition under high and low temperature conditions.

[0048] It is understandable that in the present invention, the amino acid compound is selected from Glycine, or Alanine, or a mixture of glycine and alanine, such precipitation inhibitors can significantly inhibit the precipitation of magnesium citrate and reduce the production of sodium picosulfate degradation impurity A (4-[(pyridin-2-yl)(4-hydroxyphenyl)methyl]phenyl sulfate), while significantly improving the stability of the composition under high and low temperature conditions. Further, when the amino acid compound is a mixture of glycine and alanine, the molar ratio of the two is 1: (0.01-99.9), including but not limited to 1:0.01, 1:0.05, 1:0.1, 1:0.5, 1:1, 1:2, 1:5, 1:8, 1:10, 1:15, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:95, and 1:99.9.

[0049] In one embodiment, the molar ratio of sodium picosulfate, magnesium oxide, citric acid and amino acid compound is (0.001-0.1):(10-200):(10-150):(10-200), including but not limited to: 0.001:10:10:10, 0.001:100:10:10, 0.001:200:10:10, 0.001:100:100:10, 0.001:100:100:10, 0.001:100:150:10, 0.001:100:150:10, 0.001:100:150:100, 0.001:100:150:200, 0.01:10:10:10, 0.01:100:10:10, 0.01:200:10:10, 0.01:100:100:10. .01:100:150:10, 0.01:100:150:100, 0.01:100:150:200, 0.05:10:10:10, 0.05:100:10:10, 0.05:200:10:10, 0.05:100:100:10, 0.05:100:150:10, 0.05:1 00:150:100, 0.05:100:150:200, 0.1:10:10:10, 0.1:100:10:10, 0.1:200:10:10, 0.1:100:100:10, 0.1:100:150:10, 0.1:100:150:10, and 0.1:100:150:200. Further, referring to the above records, when the amino acid compound is a mixture of glycine and alanine, the molar ratio of the two is 1:(0.01~99.9), including but not limited to 1:0.01, 1:0.05, 1:0.1, 1:0.5, 1:1, 1:2, 1:5, 1:8, 1:10, 1:15, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:95, and 1:99.9.

[0050] In one embodiment, in the pharmaceutical liquid composition, the concentration of sodium picosulfate is 0.01 mg / ml to 0.2 mg / ml, including but not limited to: 0.01 mg / ml, 0.02 mg / ml, 0.03 mg / ml, 0.04 mg / ml, 0.05 mg / ml, 0.06 mg / ml, 0.07 mg / ml, 0.08 mg / ml, 0.09 mg / ml, 0.10 mg / ml, 0.11 mg / ml, 0.12 mg / ml, 0.13 mg / ml, 0.14 mg / ml, 0.15 mg / ml, 0.16 mg / ml, 0.17 mg / ml, 0.18 mg / ml, 0.19 mg / ml, and 0.2 mg / ml.

[0051] In one embodiment, the weight ratio of sodium picosulfate, magnesium oxide, citric acid and amino acid compound is 1: (300-400): (1000-1500): (100-2000),Including but not limited to: 1:300:1000:100, 1:300:1000:200, 1:300:1000:300, 1:300:1000:400, 1:300:1000:500, 1:300:1000:600, 1:300:1000:700, 1:300:1000:800, 1:300:1000:900, 1:300:1000:1000, 1:300:1000:1100, 1:300:1000: 1200, 1:300:1000:1300, 1:300:1000:1400, 1:300:1000:1500, 1:300:1000:1600, 1:300:1000:1700, 1:300:1000:1800, 1:300:1000:1900, 1:300:1000:2000, 1:350:1200:100, 1:350:1200:200, 1:350:1200:300, 1:350:1 200:400, 1:350:1200:500, 1:350:1200:600, 1:350:1200:700, 1:350:1200:800, 1:350:1200:900, 1:350:1200:1000, 1:350:1200:1100, 1:350:1200:1200, 1:350:1200:1300, 1:350:1200:1400, 1:350:1200:1500, 1:350: 1200:1600, 1:350:1200:1700, 1:350:1200:1800, 1:350:1200:1900, 1:350:1200:2000, 1:400:1500:100, 1:400:1500:200, 1:400:1500:300, 1:400:1500:400, 1:400:1500:500, 1:400:1500:600, 1:400:1500:700, 1:400: : 1500: 1600, 1:400: 1500: 1700, 1:400: 1500: 1800, 1:400: 1500: 1900, and 1:400: 1500: 2000. Further, referring to the above description, when the amino acid compound is a mixture of glycine and alanine, the weight ratio of glycine to alanine is 1: (0.8-1.5),Including but not limited to 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5.

[0052] In one embodiment, the pharmaceutical liquid composition further comprises a pharmaceutically acceptable excipient.

[0053] In one embodiment, the auxiliary material is selected from one or more of a stabilizer, a preservative, a sweetener, a pH adjuster, a flavoring agent and an antioxidant.

[0054] In one embodiment, the stabilizer is selected from one or both of edetate disodium and edetate calcium sodium, which significantly enhances the stability and antioxidant properties of the drug. It is understood that the stabilizer is selected from edetate disodium, edetate calcium sodium, or a mixture of edetate disodium and edetate calcium sodium.

[0055] In one embodiment, the preservative is selected from one or more of sodium benzoate, methylparaben, ethylparaben, propylparaben and butylparaben, which significantly improves the antiseptic performance and storage performance of the drug. It is understandable that the preservative is selected from sodium benzoate, or methylparaben, or ethylparaben, or propylparaben, or butylparaben, or a mixture of sodium benzoate and methylparaben, or a mixture of sodium benzoate and ethylparaben, or a mixture of sodium benzoate and propylparaben, or a mixture of sodium benzoate and butylparaben, or a mixture of sodium benzoate, methylparaben and ethylparaben, or a mixture of sodium benzoate, methylparaben and propylparaben, or a mixture of sodium benzoate, methylparaben and butylparaben, or a mixture of methylparaben, ethylparaben and propylparaben, or a mixture of methylparaben, ethylparaben and butylparaben, or a mixture of ethylparaben, propylparaben and butylparaben, or a mixture of sodium benzoate, methylparaben, ethylparaben, propylparaben and butylparaben.

[0056] In one embodiment, the sweetener is selected from one or more of sucralose, sucrose, acesulfame potassium, mannitol and aspartame, which significantly improves the palatability of the drug and enhances the sensory experience.

[0057] In one embodiment, the pH adjuster is selected from one or more of sodium hydroxide, potassium hydroxide, ammonia solution, triethanolamine, potassium citrate, sodium bicarbonate, potassium bicarbonate and sodium citrate to adjust the pH value.

[0058] In one embodiment, the fragrance is selected from one or more of sweet orange flavor, strawberry flavor, orange flavor, vanilla flavor and mixed fruit flavor, which significantly improves the smell of the medicine and enhances the sensory experience.

[0059] In one embodiment, the antioxidant is selected from one or both of sodium metabisulfite and vitamin C, which significantly improves the antioxidant property of the drug and makes the drug more stable.

[0060] In the present invention, the addition amount of various auxiliary materials can be reasonably limited by those skilled in the art according to actual needs and is not limited here.

[0061] In one embodiment, the pH value of the pharmaceutical liquid composition is 3.0-8.0, including but not limited to 3.0, 3.5, 4.0, 4.2, 4.4, 4.5, 4.9, 5.0, 5.2, 5.4, 5.5, 5.9, 6.0, 6.2, 6.4, 6.5, 6.9, 7.0 and 8.0. Furthermore, the pH value of the pharmaceutical liquid composition is 4.1-6.0.

[0062] The present invention also provides a method for preparing the above-mentioned liquid pharmaceutical composition, comprising the following steps:

[0063] Combine water, sodium picosulfate, magnesium oxide, citric acid, and amino acid compound.

[0064] In one embodiment, the mixing comprises:

[0065] Mixing magnesium oxide and citric acid in water to prepare mixture S1;

[0066] Mixing the mixture S1 with an amino acid compound to prepare a mixture S2;

[0067] The mixture S2 was mixed with sodium picosulfate.

[0068] Furthermore, the preparation method of the pharmaceutical liquid composition further comprising pharmaceutically acceptable excipients comprises the following steps:

[0069] Mixing the magnesium oxide and citric acid in water to prepare a mixture S1;

[0070] Mixing the mixture S1 with an amino acid compound to prepare a mixture S2;

[0071] Mixing the mixture S2 with a pharmaceutically acceptable excipient to prepare a mixture S3;

[0072] The mixture S3 is mixed with sodium picosulfate.

[0073] The present invention also provides use of the above-mentioned liquid pharmaceutical composition in the preparation of a laxative.

[0074] The present invention also provides use of the above-mentioned liquid pharmaceutical composition in preparing a colon cleansing agent.

[0075] Example

[0076] The present invention will be further described below with reference to specific embodiments.

[0077] Examples 1 to 15 and Comparative Examples 1 to 9

[0078] The following examples provide a liquid composition containing sodium picosulfate and a preparation method thereof, as follows:

[0079] (1) The prescriptions of Examples 1 to 15 are shown in Tables 1 to 2 below, and the prescriptions of Comparative Examples 1 to 9 are shown in Table 3 below.

[0080] (2) Preparation method: In purified water, dissolve magnesium oxide and citric acid in the prescribed amounts shown in Tables 1 to 3, add amino acids, then add other excipients, and finally add sodium picosulfate to dissolve. Adjust the pH value of the pharmaceutical liquid composition to the target value with 3 mol / L sodium hydroxide solution to obtain the product.

[0081] Table 1

[0082] Table 2

[0083] Table 3

[0084] test:

[0085] 1. The contents of sodium picosulfate, magnesium oxide and citric acid in Examples 1 to 15 and Comparative Examples 1 to 9 were determined by liquid chromatography. The results are shown in Table 4 below.

[0086] Table 4

[0087] As shown in Table 4, there is no significant difference in the content of the main components between Examples 1 to 15 and Comparative Examples 2 to 9 compared to Comparative Example 1. Therefore, it can be considered that the liquid compositions of Examples 1 to 15 of the present invention are similar to the products available on the US market (CLENPIQ TM ) has the same or similar effects as a colon cleanser.

[0088] 2. The pharmaceutical liquid compositions prepared in Examples 1 to 15 and Comparative Examples 1 to 9 were placed under high temperature (60° C.) conditions for 30 days to compare the changes in sodium picosulfate impurity A (4-[(pyridin-2-yl)(4-hydroxyphenyl)methyl]phenyl sulfate). The results are shown in Table 5 below.

[0089] Table 5

[0090] As shown in Table 5, under high temperature conditions and at a high pH value, when the liquid composition contains one or both of glycine and alanine, the effect of reducing the formation of impurity A is better than that of malic acid, tartaric acid, malonic acid, succinic acid, serine and tryptophan.

[0091] 3. The pharmaceutical liquid compositions prepared in Examples 1 to 15 and Comparative Examples 1 to 9 were placed under freeze-thaw cycles (-20°C, 25°C cycles) for 10 cycles to compare the changes in magnesium citrate precipitation. The results are shown in Table 6 below.

[0092] Table 6

[0093] As shown in Table 6, glycine and alanine have better effects on inhibiting precipitation during freeze-thaw cycles compared with malic acid, tartaric acid, malonic acid, succinic acid, serine and tryptophan.

[0094] The technical features of the above-described embodiments may be combined in any manner. To simplify the description, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there are no contradictions in the combination of these technical features, they should be considered to be within the scope of this specification.

[0095] The above-described embodiments merely illustrate several implementations of the present invention, and while their descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the patent. It should be noted that a person skilled in the art would be able to make numerous variations and improvements without departing from the spirit of the present invention, all of which fall within the scope of protection of the present invention. Therefore, the scope of protection of the patent for this invention shall be determined by the appended claims.

Claims

1. A liquid pharmaceutical composition, characterized in that: Includes water, sodium picosulfate, magnesium oxide, citric acid and amino acid compounds; The amino acid compound is selected from one of glycine and alanine or a mixture of the two.

2. The pharmaceutical liquid composition according to claim 1, characterized in that The molar ratio of sodium picosulfate, magnesium oxide, citric acid and amino acid compound is (0.001-0.1): (10-200): (10-150): (10-200); In the pharmaceutical liquid composition, the concentration of sodium picosulfate is 0.01 mg / ml to 0.2 mg / ml.

3. The pharmaceutical liquid composition according to claim 1, characterized in that The pH value of the pharmaceutical liquid composition is 3.0-8.

0.

4. The pharmaceutical liquid composition according to any one of claims 1 to 3, characterized in that: Pharmaceutically acceptable excipients are also included.

5. The pharmaceutical liquid composition according to claim 4, characterized in that: The auxiliary material is selected from one or more of a stabilizer, a preservative, a sweetener, a pH adjuster, a fragrance and an antioxidant.

6. The pharmaceutical liquid composition according to claim 5, characterized in that: The stabilizer is selected from one or both of edetate disodium and edetate calcium sodium; and / or The preservative is selected from one or more of sodium benzoate, methylparaben, ethylparaben, propylparaben and butylparaben; and / or The sweetener is one or more selected from sucralose, sucrose, acesulfame potassium, mannitol and aspartame; and / or The pH regulator is selected from one or more of sodium hydroxide, potassium hydroxide, ammonia solution, triethanolamine, potassium citrate, sodium bicarbonate, potassium bicarbonate and sodium citrate; and / or The aromatic agent is selected from one or more of sweet orange flavor, strawberry flavor, orange flavor, vanilla flavor and mixed fruit flavor; and / or The antioxidant is selected from one or both of sodium pyrosulfite and vitamin C.

7. The method for preparing the pharmaceutical liquid composition according to any one of claims 1 to 6, characterized in that: The steps include: The water, sodium picosulfate, magnesium oxide, citric acid and amino acid compound are mixed.

8. The method for preparing the pharmaceutical liquid composition according to claim 7, characterized in that: The mixing includes: The magnesium oxide and citric acid are mixed in water to prepare a mixture S1; Mixing the mixture S1 with an amino acid compound to prepare a mixture S2; The mixture S2 was mixed with sodium picosulfate.

9. Use of the liquid pharmaceutical composition according to any one of claims 1 to 6 in the preparation of a laxative.

10. Use of the liquid pharmaceutical composition according to any one of claims 1 to 6 in the preparation of a colon cleansing agent.

Citation Information

Patent Citations

  • Liquid pharmaceutical composition

    CN106456534A

  • Liquid formulations containing picosulfate and magnesium citrate

    CN109310774A

  • Medicinal liquid composition as well as preparation method and application thereof

    CN116585261A

  • Stabilized liquid formulations containing picosulfate

    US20180015078A1